triamcinolone (TAC, Arsitospan, Kenalog, Trivaris)
Jump to navigation
Jump to search
Introduction
Systemic agent: Tradenames: Aristocort, Kenacort, Kenalog.
Indications
- anti-inflammatory agent (systemic, topical)
Dosage
Tabs: 1, 2, 4, 8 mg
Syrup: 4 mg/5 mL.
Injection: Kenalog, Trivaris
Adverse effects
- common (> 10%)
- increased appetite, insomnia, indigestion, nervousness 2)less common (1-10%)
- uncommon (< 1%)
- seizures, mood swings, headache, skin atrophy, bruising, hyperpigmentation, acne, amenorrhea, Na+ & H20 retention, Cushing's syndrome, suppression of bone growth, abdominal distention, ulcerative esophagitis, pancreatitis, muscle wasting, hypersensitivity, delirium, hallucinations, euphoria
- short-term
- fluid & electrolyte disturbances
- hyperglycemia
- poor wound healing
- GI disturbances
- spread of infection
- long-term
- osteoporosis
- bone fractures
- pituitary adrenal axis insufficiency
- Cushing's syndrome
- acute adrenal insufficiency with rapid withdrawal of therapy
- skin atrophy
- hyperpigmentation
Drug interactions
- aminoglutethimide
- anticholinesterases
- barbiturates
- carbamazepine
- phenytoin
- rifampin
- live virus vaccines
- drug interaction(s) of methotrexate with biological response modifier
- drug interaction(s) of glucocorticoids with warfarin
- drug interaction(s) of NSAIDs with glucocorticoid
Mechanism of action
- intermediate-acting glucocorticoid
More general terms
More specific terms
- Triamcinolone Inhalation (Azmacort)
- Triamcinolone Nasal (Nasocort)
- Triamcinolone Topical (Aristocort, Kenacort)
Component of
- neomycin/nystatin/thiostrepton/triamcinolone
- nystatin/triamcinolone (Mycolog II, Mycogen II, Tri-Statin II)
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 85.
- ↑ Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 743
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
- ↑ Journal Watch, Mass Med Soc 20(11):88 (June) 2000
Wong CA, Walsh LJ, Smith CJ et al Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000 Apr 22;355(9213):1399-403 PMID: https://www.ncbi.nlm.nih.gov/pubmed/10791523
Sambrook PN Inhaled corticosteroids, bone density, and risk of fracture. Lancet 355:1385, 2000 PMID: https://www.ncbi.nlm.nih.gov/pubmed/10791519
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=31307
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5544
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6216
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6436
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=21826
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62963
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62964
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=633097
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=539244
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16147
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=633091
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5545
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=657338